Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shandong Boan Biotechnology CoFRA:UJ9 39 PE Ratio (TTM) is 560.00 as of Jul. 22, 2026, which is 527% above its 10-year median of 89.33. GuruFocus rates FRA:UJ9 with a GF Score™ of 39/100 and a GF Value™ of €1.75. The stock has 5 warning signs investors should review. Among 269 Biotechnology companies, Shandong Boan Biotechnology Co ranks worse than 98.88% on this metric.
During the past 6 years, Shandong Boan Biotechnology Co's highest 3-Year average EPS without NRI Growth Rate was 23.40% per year. The lowest was 23.40% per year. And the median was 23.40% per year.
Shandong Boan Biotechnology Co (FRA:UJ9) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
Shandong Boan Biotechnology Co PE Ratio (TTM) Related Terms
Shandong Boan Biotechnology Co PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co PE Ratio (TTM) Chart
FRA:UJ9 vs VRTX, REGN, ALNY: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's PE Ratio (TTM) falls into.
Shandong Boan Biotechnology Co PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Shandong Boan Biotechnology Co's Share Price of today is €0.56.
For company reported semi-annually, Shandong Boan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Shandong Boan Biotechnology Co (FRA:UJ9) has a PE Ratio (TTM) of 560.00 as of Jul. 22, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Shandong Boan Biotechnology Co and its competitors. This is 527% above median its historical median of 89.33. Over the past decade, Shandong Boan Biotechnology Co's PE Ratio (TTM) has ranged from 54.97 to 861.82. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #266 out of 269 companies in the Biotechnology industry, placing it in the top 98.9%.
Is Shandong Boan Biotechnology Co's PE Ratio (TTM) too high?
Shandong Boan Biotechnology Co's current PE Ratio (TTM) of 560.00 is 527% above median its 10-year median of 89.33. Over the past 10 years, this metric has ranged from a low of 54.97 to a high of 861.82. The Biotechnology industry median PE Ratio (TTM) is 27.88. Shandong Boan Biotechnology Co's value of 560.00 is 1908.6% above this industry median. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #266 out of 269 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's PE Ratio (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #266 out of 269 companies for PE Ratio (TTM). This places Shandong Boan Biotechnology Co in the lower half of its industry. The industry median PE Ratio (TTM) is 27.88. Shandong Boan Biotechnology Co's value of 560.00 is 1908.6% above this benchmark. Historically, Shandong Boan Biotechnology Co's own PE Ratio (TTM) has ranged from 54.97 to 861.82 over the past decade. While the company's 10-year median is 89.33 vs. the industry median of 27.88, Shandong Boan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 27.88, based on 269 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Boan Biotechnology Co's current PE Ratio (TTM) of 560.00 is 1908.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on Shandong Boan Biotechnology Co and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 27.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current PE Ratio (TTM) is 560.00, which is 527% above median its own 10-year median of 89.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current PE Ratio (TTM) of 560.00. The stock's GF Value™ is €1.75, compared to a current price of €0.56 — trading 68% below its estimated fair value. The current PE Ratio (TTM) is 560.00, which is 527% above median its 10-year median of 89.33 and 1908.6% above the Biotechnology industry median of 27.88. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current PE Ratio (TTM) is 560.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.56 is trading 68% below its estimated GF Value™ of €1.75.
Key valuation signals for FRA:UJ9:
PE Ratio (TTM): 560.00 (527% above median its 10-year median of 89.33)
GF Value™: €1.75 vs. price of €0.56 (68% below fair value)
Industry Position: 1908.6% above the Biotechnology median (#266 of 269)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score
Get the complete analysis for FRA:UJ9
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
